Results 71 to 80 of about 13,254 (218)

Pyoderma Gangrenosum as the First Manifestation of Inflammatory Bowel Disease: A Case Report

Case Reports in Gastrointestinal Medicine, Volume 2026, Issue 1, 2026.
Approximately 50% of patients with inflammatory bowel disease (IBD) exhibit extraintestinal manifestations, among which skin and mucosal lesions are common. However, pyoderma gangrenosum occurs in only 1%‐2% of IBD patients. We report the case of a 23‐year‐old male patient who was admitted to the hospital with pyoderma gangrenosum that was unresponsive
Nam Hoai Nguyen, Tan Thi Tran, Trang Thu Khuc, Yen Thi Lo, Ha Thi-Ngoc Doan, Hieu Van Nguyen, Long Cong Nguyen, Marcel Cc Machado   +7 more
wiley   +1 more source

Myelodysplastic Syndrome With Complex Chromosomal Karyotype Abnormalities Complicated by Multiple Intestinal Perforations: A Case Report and Literature Review

Case Reports in Gastrointestinal Medicine, Volume 2026, Issue 1, 2026.
Background Myelodysplastic syndromes (MDSs) are clonal hematopoietic disorders often associated with cytogenetic abnormalities, among which trisomy 8 is one of the most common abnormalities. Trisomy 8 is linked to autoimmune manifestations, including Behçet‐like disease, especially with gastrointestinal involvement.
Zhan-Yue Niu, Ming-Fei Zhu, Ming Tao, Cheng Zhang, Fang Gu, Jun Li, MARCEL CC MACHADO   +6 more
wiley   +1 more source

Comparative review of imipenem/cilastatin versus meropenem.

Médecine et maladies infectieuses, 2020
INTRODUCTION Carbapenems are broad-spectrum antibacterial molecules. Imipenem-cilastatin and meropenem are the two main molecules used in French healthcare services.
A. Salmon-Rousseau, C. Martins, M. Blot, M. Buisson, S. Mahy, P. Chavanet, L. Piroth   +6 more
semanticscholar   +1 more source

Validated Reverse Phase HPLC Method for the Determination of DEHP Content in Reconstituting Diluents and in Reconstituted Solutions of Imipenem and Cilastatin for Injection

E-Journal of Chemistry, 2010
A simple, rapid, accurate and economic reverse phase HPLC method was developed and validated for determination of di-(2-ethylhexyl)phthalate (DEHP) in reconstituting diluents and reconstituted solutions of imipenem and cilastatin for injection The method
A. K. Chaudhary, S. Ankushrao Waske, S. Yadav, T. G. Chandrashekhar, Vandana Singh   +4 more
doaj   +1 more source

H1N1‐Related Hemophagocytic Lymphohistiocytosis Complicated by Severe Rhabdomyolysis in a Pediatric Patient: A First Case Report

Case Reports in Pediatrics, Volume 2026, Issue 1, 2026.
Background Hemophagocytic lymphohistiocytosis (HLH) is a rare and often life‐threatening hyperinflammatory disorder, mainly caused by infections, malignancies, or autoimmune diseases. Influenza A (H1N1) has occasionally been linked to pediatric HLH cases.
Lucia Marseglia, Antonella Gambadauro, Federica Xerra, Annalisa Cacciola, Immacolata Rulli, Valeria Chirico, Raffaella Mallamace, Eloisa Gitto, Kaylita Chantiluke   +8 more
wiley   +1 more source

Abstract Supplement

Pulmonary Medicine, Volume 2026, Issue 1, 2026.
 
Marzia Folegani, Semonti Nandi
wiley   +1 more source

Protective effect of cilastatin against diclofenac‐induced nephrotoxicity through interaction with diclofenac acyl glucuronide via organic anion transporters

British Journal of Pharmacology, 2020
Diclofenac is a widely used nonsteroidal anti‐inflammatory drug. However, adverse effects in the kidney limit its clinical application. The present study was aimed to evaluate the potential effect of cilastatin on diclofenac‐induced acute kidney injury ...
Xiaokui Huo, Q. Meng, Changyuan Wang, Jingjing Wu, Chong Wang, Yanna Zhu, Xiaodong Ma, Huijun Sun, Kexin Liu   +8 more
semanticscholar   +1 more source

Diagnosis, Prognosis, and Drug Target Discovery for Chronic Widespread Pain: A Large Proteogenomic Study

Advanced Science, Volume 12, Issue 47, December 18, 2025.
Plasma proteomics is leveraged to decode the biological underpinnings of chronic widespread pain. A nested machine learning framework integrates proteomic signatures, prospective outcomes, and Mendelian randomization to uncover 18 causal proteins.
Li Chen, Eoin Kelleher, Ruogu Meng, Duanke Liu, Yuchen Guo, Yunhe Wang, Yaqing Gao, Zhe Huang, Zhu Liang, Shuai Yuan, Chao Zeng, Jun Ma, Yanhui Dong, Anushka Irani, Guanghua Lei, Junqing Xie, Daniel Prieto‐Alhambra   +16 more
wiley   +1 more source

Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections

Antimicrobial Agents and Chemotherapy, 2020
The RESTORE-IMI 1 phase 3 trial demonstrated the efficacy and safety of imipenem-cilastatin (IMI) combined with relebactam (REL) for treating imipenem-nonsusceptible infections.
K. Kaye, H. Boucher, M. Brown, Angela A. Aggrey, I. Khan, Hee-Koung Joeng, R. Tipping, Jiejun Du, K. Young, J. Butterton, Amanda Paschke   +10 more
semanticscholar   +1 more source

A multicenter, double-blind, randomized, comparison study of the efficacy and safety of tigecycline to imipenem/cilastatin to treat complicated intra-abdominal infections in hospitalized subjects in China

Therapeutics and Clinical Risk Management, 2018
Yijian Chen,1,2,* Demei Zhu,1,2,* Yingyuan Zhang,1,2 Yongjie Zhao,3 Gang Chen,4 Ping Li,5 Lihong Xu,6 Ping Yan,6 M Anne Hickman,7 Xiajun Xu,6 Margaret Tawadrous,7 Michele Wible7 1Institute of Antibiotics, Huashan Hospital Fudan University, Shanghai ...
Chen Y, Zhu D, Zhang Y, Zhao Y, Chen G, Li P, Xu L, Yan P, Hickman MA, Xu X, Tawadrous M, Wible M   +11 more
doaj